CASP3 and glioblastoma: Accordingly, Bcl-xL overexpression inhibited caspase-3 activation in GBM cells treated with TRAIL and PIM kinases inhibitor for 22 h (Fig. 4C) confirming that U87MG GBM cells are type II cells that require amplification of apoptosis signaling through the mitochondria.